AstraZeneca says an imbalanced adult subgroup sank its Ph3 HICKORY trial of efzimfotase alfa in hypophosphatasia as the FDA ...
When it made its much-hyped Mythos available back on July 1, Anthropic said the AI model was so powerful it couldn’t allow the technology to be used for life sciences tasks. On Thursday, ...
Fresh from its rebrand last week, Novo CEO Maziar Mike Doustdar spelled out the strategic vision that goes along with it. At the Danish drugmaker’s capital markets day in London on Monday ...
Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient ...
Chan Zuckerberg Biohub launches $1.8B Virtual Biology Initiative with Meta, Google DeepMind, Isomorphic Labs, DOE, and NIH to ...
Welcome back to Endpoints Weekly! We unveiled our 2026 Women in Biopharma special project on Monday. Our team pored through nearly 200 nominations to reach this year’s list of 20 ...
FDA opens Office of Innovation and Clinical Trial Modernization within CDER, with Marie Bradley as acting director of the ...
Curium prices Bexlutry, its copycat of Novartis’ radioligand Lutathera, at $63,524 per infusion, about 5% below the original.
Ultragenyx sells a rare pediatric disease PRV for $210M, one of 2026's priciest voucher deals, and plans to monetize a second ...
City Therapeutics eyes $158M IPO; Iambic Therapeutics targets $135M; Alchemist Capital launches with $100M; Life Biosciences ...
Epicrispr's epigenetic editor EPI-321 shows a 3% gain in muscle volume in FSHD patients at 6 months, alongside one case of ...
Leerink's David Risinger downgrades Bristol Myers to market perform and cuts his price target to $59, citing doubts on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results